GET DAILY SIGNALSArrowhead Pharmaceuticals (ARWR): Weighing the Path to the $108 Analyst Target
Key Takeaways
- The central target of $108 is the arithmetic mean of roughly 15 current analyst price targets reviewed for this analysis, rounded from an underlying average near $108.
- The latest verified closing price is $58.16, meaning the target implies an upside of roughly 85%.
- Individual analyst targets range widely, from about $74 (Goldman Sachs) to $126 (Piper Sandler); some sources also list a more cautious $46 target from Bernstein, underscoring how divided the Street remains.
- The consensus rating is a Strong Buy, reflecting optimism about Arrowhead's cardiometabolic and neurology pipeline.
- Strongest supports include the commercial launch of REDEMPLO and positive plozasiran data, while the biggest risks are competition, persistent net losses, and rate-driven valuation pressure on biotech.
- For more context, explore Major News, Today's Price Move, the AI-driven Forecast, and upcoming Earnings for ARWR.
- To see how AI evaluates this and thousands of other securities, explore Trending AI Robots.
Breaking Down the Analyst Targets
The $108 central target is a calculated average, not a single firm's published number. Aggregating the most recent individually attributable targets, the Street's view spans a wide band. On the bullish end, Piper Sandler has reiterated a $126 target and H.C. Wainwright a $120 target. UBS initiated coverage at $109, and Citi has maintained a $108 target. Nearer the middle sit targets from firms such as J.P. Morgan ($88) and RBC Capital ($87). On the cautious side, Goldman Sachs resumed coverage with a Neutral rating and a $74 target, while a separate, older Bernstein target of $46 remains in some databases and illustrates how far apart analysts' base cases can be.
This dispersion reflects genuine disagreement about how much of ARWR's pipeline value should be discounted today. Bullish analysts emphasize the de-risking of the cardiometabolic franchise and optionality in obesity and central nervous system (CNS) programs. More cautious analysts argue the shares already price in substantial future execution on a product that is still early in its commercial ramp. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry. The average analyst price target should be read as a statistical midpoint across those views, not a guaranteed stock forecast.
Where ARWR Stands Today
Arrowhead closed at $58.16 on November 6, 2026, near the middle of a 52-week range of $37.06 to $95.49. Reaching $108 would require a gain of roughly 85% from that level, a very large move by any measure. The stock is down about one-third over the past three months, a reminder that sentiment toward development-stage biotech can shift quickly even when clinical data is broadly positive.
The path toward $108 would likely require sustained, positive news flow across the pipeline. Arrowhead's approved drug, REDEMPLO (plozasiran), targets familial chylomicronemia syndrome, an ultra-rare condition causing severely elevated triglycerides, and the company is pursuing a broader label in severe hypertriglyceridemia. At the American Heart Association Scientific Sessions in early November 2026, pooled Phase 3 data showed plozasiran reduced acute pancreatitis event rates by 78% overall, strengthening the case for the broader indication. Arrowhead also reported interim ARO-MAPT data showing up to 73% reduction in cerebrospinal fluid tau, a marker relevant to Alzheimer's disease, extending the platform into the CNS.
Potential Catalysts Ahead
Several factors could support appreciation toward $108. First, plozasiran's clinical profile is strong: sustained triglyceride reductions and hard-endpoint pancreatitis data give it a differentiated position, and the FDA has accepted the severe hypertriglyceridemia application into its STAR pilot program, potentially shortening the review timeline. Second, Arrowhead's RNAi platform continues to expand into new therapeutic areas, including obesity candidates ARO-INHBE and ARO-ALK7 and the ARO-DIMER-PA dual LDL/triglyceride candidate, providing multiple shots on goal. Third, partnerships with companies such as Novartis and Sarepta Therapeutics provide non-dilutive funding and validation, and Arrowhead reported roughly $1.6 billion in cash and securities as of mid-2026, supporting a multi-year runway.
Key Risks to Consider
The obstacles are substantial. Arrowhead remains unprofitable, with a trailing net loss of about $320 million, and the stock trades at no meaningful earnings multiple, making it sensitive to changes in risk appetite and interest rates. Competition is real: Ionis Pharmaceuticals' olezarsen is a direct rival in the same cardiometabolic market, and pricing and market-share dynamics in hypertriglyceridemia remain uncertain. Many of the programs that justify the highest price targets, including the obesity and CNS candidates, are still in early-stage trials, meaning a single disappointing readout could compress valuation quickly. A November 2026 refinancing of a $400 million credit facility improved terms but added debt to a company already carrying leverage.
Looking at the Charts
From a technical standpoint, ARWR is trading below its 50-day moving average near $67 and its 200-day moving average near $72, which now act as overhead supply zones rather than support. The stock's 52-week high of $95.49 marks a significant resistance area, while $37.06 represents the major support floor from the past year. Reclaiming the $70s would be a meaningful first step, but a move to $108 would require clearing the prior high and establishing new territory, a structurally demanding setup given the current downtrend.
What to Watch Next
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different assumptions. Arrowhead reports fiscal year-end results on November 12, 2026, a key event for guidance and pipeline updates. Beyond that, investors should watch the severe hypertriglyceridemia regulatory path, additional obesity and CNS data readouts, prescription trends for REDEMPLO, partnership milestones, and any shifts in analyst ratings or price targets. Macroeconomic conditions, particularly Treasury yields and risk appetite toward unprofitable biotech, also matter.
Using Tickeron AI Tools in My Analysis
In my own work, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a volatile biotech like ARWR, where news can shift sentiment quickly, it helps me stay on top of trends without constant manual checks. I find it particularly useful when reviewing how clinical updates or rate moves might influence positioning over the coming weeks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARWR in +2.47% Uptrend, growing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARWR advanced for three days, in 222 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In 82 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ARWR turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 30 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
The 50-day moving average for ARWR moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARWR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. ARWR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.647) is normal, around the industry mean (3.498). P/E Ratio (-25.509) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs to treat intractable diseases
Industry Biotechnology
Advertisement